REG - Hellenic Dynamics - Notice of AGM

Hellenic DynamicsAnnouncement

07/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230907:nRSG6369La&default-theme=true

RNS Number : 6369L  Hellenic Dynamics PLC  07 September 2023

7 September 2023

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

 

Notice of Annual General Meeting and Form of Proxy

 

Hellenic Dynamics Plc (LSE: HELD), a medical cannabis cultivator specifically
focused on the cultivation and supply of tetrahydrocannabinol dominant
strains of medical cannabis flowers destined for the rapidly growing medical
cannabis markets across Europe, announces that its Notice of Annual General
Meeting ("AGM") and Form of Proxy ("Proxy") were posted to shareholders on 6
September 2023.

 

Both the Notice of AGM and the Proxy will shortly be uploaded to the National
Storage Mechanism and will be available at:
www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism
(http://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism)
.

 

These documents, as well as the Annual Report for year ended 31 March 2023,
are also available on the Company's website at:
https://www.hellenicdynamics.com (https://www.hellenicdynamics.com) .

 

The AGM will be held on 29 September 2023 at 13:00 at the offices of
Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.

 

The Directors of the Company take responsibility for the contents of this
announcement.

 

Enquires:

 

Hellenic Dynamics plc
                               +44 (0)20 3818
7850

Davinder Rai
 
davinder@hellenicdynamics.com

 

Cairn Financial Advisers LLP

Emily Staples / Jo Turner
+44 (0)20 7213 0880

 

Peterhouse Capital

Lucy Williams / Charles Goodfellow        +44 (0)20 7469 0930

 

J&H Communications

George Hudson
 
+44 (0)7803 603130

About Hellenic Dynamics plc

 

Founded in 2019, Hellenic Dynamics is specifically focused on the cultivation
and supply of tetrahydrocannabinol ("THC") - dominant strains of medical
cannabis flowers, destined for the growing medical cannabis markets
across Europe. Hellenic Dynamics' core strategy is to develop and operate its
40,000 square metre active cultivation licence from its 195,506 square metre
facility located near Thessaloniki in Northern Greece. In full production,
Hellenic Dynamics is capable of producing over 54,000 kg of dried flowers per
annum.

 

Hellenic Dynamics will take advantage of its relatively low cost base
resulting from a comparatively low cost of power, having its own running
water supply and the labour rates for skilled and semi-skilled labour in
Northern Greece.

 

25 European countries now allow medical cannabis via prescription and the
European cannabis market is expected to reach €43.3 billion per annum by
2027. Sales of Hellenic Dynamics' dried THC-dominant cannabis flowers and
extracts are initially intended for export into Europe's largest market -
Germany, in addition to other European markets including domestically in
Greece.

 

As the first medical cannabis cultivator to obtain a listing on the main
market for listed securities of the London Stock Exchange, Hellenic is
significantly different to the number of CBD (Cannabidiol) related companies
that have appeared over the recent years. Hellenic Dynamics cultivates
THC-dominant medical cannabis flowers. THC-dominant medical cannabis products
are only available via a medical prescription. Medicinal cannabis has been
approved for use both in the United Kingdom and Germany, plus 23 other
European countries, for conditions including but not limited to  chronic
pain, intractable chemotherapy-related nausea, anxiety, insomnia,
Tourette's syndrome, substance use disorder, multiple sclerosis, IBS, spinal
cord treatment, lack of appetite due to HIV/AIDS, cachexia, anorexia and
glaucoma.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOALFMMTMTBMTRJ